Bimekizumab Demonstrates Long-Term Efficacy in Psoriasis Treatment

In a groundbreaking study presented at the Society of Dermatology Physician Assistants (SDPA) 2025 conference, findings from the BE BRIGHT trial indicate that bimekizumab, a novel therapeutic agent, shows sustained efficacy and safety over a five-year period in patients suffering from moderate to severe plaque psoriasis. The trial’s results, which were disclosed between June 25 and June 29, 2025, in Washington, D.C., reveal that patients undergoing continuous bimekizumab therapy maintained impressive rates of improvement as measured by the Psoriasis Area and Severity Index (PASI).

The BE BRIGHT trial, an extension of previous phase 3 studies including BE VIVID and BE SURE, involved a cohort of 153 participants with a mean age of 45.7 years. Notably, 66.7% of subjects were male, and 81% were White. The baseline PASI score averaged at 19.7, indicating significant disease severity at the start of the trial. Over the five-year period, 84.9% of participants achieved a PASI 90 response rate, denoting at least 90% reduction in psoriasis severity. Furthermore, a remarkable 76.9% attained PASI 100, indicating complete skin clearance.

According to Dr. Andrew Blauvelt, lead investigator and President of Blauvelt Consulting, “Bimekizumab not only demonstrated high rates of clinical response but also significantly improved quality of life for patients. The durability of these results over five years suggests that bimekizumab could be a viable long-term treatment option for patients with psoriasis.”

The trial reported a low incidence of serious treatment-related adverse events (TEAEs), with a rate of only 3.6% across the duration of the study. Common side effects included nasopharyngitis, oral candidiasis, and upper respiratory infections, which were predominantly mild to moderate in severity. Critically, no new safety concerns emerged during the trial, reinforcing the drug's favorable safety profile.

Dr. Sarah Johnson, a dermatologist at Harvard Medical School, emphasized the importance of these findings. “The sustained efficacy shown in the BE BRIGHT trial marks a significant advancement in psoriasis treatment. It provides clinicians with a powerful tool to manage a condition that profoundly affects patients' quality of life.”

The BE BRIGHT trial’s design included an open-label extension phase, which allowed for continuous administration of bimekizumab every eight weeks. Notably, among the subgroup of patients who received bimekizumab every four weeks initially, the PASI 90 response rate climbed to 96.2% by week 16, showcasing the potential benefits of an intensified dosing schedule.

As the dermatology community anticipates further research and potential regulatory review, the implications of these results are significant. With psoriasis affecting millions globally, the continued study of bimekizumab could reshape treatment paradigms. The findings also align with the World Health Organization's emphasis on improving access to effective therapeutic options for chronic skin diseases.

Looking ahead, the dermatology field may witness a shift in treatment strategies, integrating bimekizumab as a cornerstone for managing plaque psoriasis. The focus will likely remain on refining dosing regimens and identifying patient populations that may benefit the most from this therapy.

In conclusion, the BE BRIGHT trial not only underscores the long-term efficacy of bimekizumab but also highlights the ongoing need for innovative treatments in the management of plaque psoriasis. As the landscape of dermatological therapies continues to evolve, bimekizumab stands out as a promising option for sustained patient improvement and quality of life enhancement.